Particle.news
Download on the App Store

Nearly 23 Million U.S. Adults Meet 2025 Hypertension Guideline Drug Criteria, Study Finds

Treating all guideline-eligible people could substantially cut deaths yet the analysis rests on single-visit blood-pressure readings and nonrandomized data.

Overview

  • The Journal of the American Heart Association analysis, published Wednesday, estimated 22.8 million U.S. adults meet the 2025 AHA/ACC criteria for blood-pressure–lowering medication.
  • Researchers found 9.7 million of those eligible, about 43 percent, were not receiving antihypertensive drugs at the time of the NHANES 2009–2018 surveys.
  • Among eligible adults, medication use was associated with a 23 percent lower all-cause mortality and a 50 percent lower cardiovascular mortality over follow-up compared with no treatment.
  • When the team modeled full treatment of the untreated eligible group they projected roughly 200,000 all-cause deaths and 162,000 cardiovascular deaths could be prevented over 10 years.
  • Authors and guideline leaders stress lifestyle change and individualized risk assessment using the AHA PREVENT equations, and they caution that single-visit blood-pressure measures and nonrandomized treatment limit causal certainty and the precision of the estimates.